GPC3 and hepatocellular carcinoma: Recently, in a phase I trial, CAR-GPC3 T cells expressing RUNX3 (which promotes the infiltration of CD8 + T cells into tumors) were used to treat 6 HCC patients with an acceptable safety profile.